Medscape’s Post

Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians (Version 1, Update Alert) This Update Alert summarizes the impact of new evidence from a surveillance search relevant to recommendations presented in the American College of Physicians (ACP) living clinical guideline on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults (version 1) (1). The ACP Center for Evidence Reviews (CER) at the Portland Veteran Affairs Research Foundation identified 4 new published studies (2–5) and 1 post hoc analysis (6) that met the inclusion criteria of the surveillance search between 1 January 2022 (last search date for version 1 of the living systematic review) and 28 September 2023 (7). The CER’s surveillance (8) describes the studies found and determined that the new studies would not likely change the prior conclusions of the living systematic review for the benefits and harms of any included treatments (7). #Osteoporosis #LowBoneMass https://lnkd.in/g8KsUb7i

Academic Consortium member, The Ohio State University Wexner Medical Center is dedicated to creating person-centered solutions to best meet each patient’s needs, and new research reveals an opportunity for Ohio State to lead the way in improving care for patients with sickle cell disease. Senior study author Maryanna Klatt, PhD, clinical professor in the Department of Family and Community Medicine, and study first author Janet Childerhose, PhD, research assistant professor of Internal Medicine, found that the most profound source of distress for these patients is the anticipation before going to and time spent at acute care centers to manage their chronic pain. Next steps include considering how clinical settings may be altered to better address and reduce patient distress. Learn More ➜ https://ow.ly/b3gm50SFobf #championsofwholehealth #integrativemedicine #sicklecelldisease #research

Another helpful resource to learn about deprescribing!

Meet our invited speaker at #CGAIGC24, Kirk Wangensteen. An Associate Professor of Medicine at Mayo Clinic, Dr. Wangensteen serves as the director of the gastrointestinal neoplasia clinic. Learn more about his research in #HereditaryGICancer: bit.ly/3YyZnSB

https://lnkd.in/e7fEGY2j #naturopathicmedicine #pmdalliance This NeuroLife Online review focuses on a different approach. Do you consider your friends medicine? Check it out!

🤗 Call for Reading Title: Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19 👉 Full Text available here: https://lnkd.in/gsdd2tuv Journal of Clinical Medicine (JCM) MDPI #COVID19 #postCOVID

Update & response to a recent systematic review and meta-analysis on the clinical impact of inpatient medication reviews & deprescribing interventions, published by Carollo et al. in the Journal of the American Geriatrics Society (JAGS):   Carollo et al.’s analyses found interventions to significantly reduce probability of hospital readmissions between 1-12 months.   Co-authors Dr. Todd Lee, Emily McDonald, Lisa McCarthy, and Émilie Bortolussi-Courval added important missing data from randomized controlled trials, notably from 4,975 patients in the MedSafer study, and excluded non-RCT data from the analysis. The updated analysis found a reduced probability of hospital readmission only between 1-3 months, with no significant reductions at 6 and 12 months. Co-authors conclude it is highly likely that inpatient deprescribing interventions reduce the risk of short-term readmission.   As more deprescribing data becomes available, authors recommend adopting “a living systematic review approach” for RCTs, with the addition of new data as they emerge: https://lnkd.in/evVUE-9z Access Carollo et al.'s systematic review & meta-analysis here: https://lnkd.in/gzzN5Hgf

💡 Did You Know? The Determi-Nation Patient Navigator Program, created by SUNY Downstate Health Sciences University, has set out to address the significant disparities faced by patients with SOC in dermatological care, including limited access to dermatologists, diagnostic delays, and reduced availability of advanced therapies. The program aims to identify and support underserved patients by pairing them with medical students to create a vital link between individuals and their medical care teams. Johnson & Johnson Innovative Medicine 🔗 Learn more: https://lnkd.in/eUpQK9Z3 #LiVDerm #Psoriasis

Learn more about exposomes.. the next frontier of individualized medicine.

Dr Anjay Rastogi (David Geffen School of Medicine UCLA, US) and Dr Clara Bonanad (University Clinical Hospital of Valencia, ES) discuss the evolving management strategies of hyperkalaemia in heart failure and chronic kidney disease, in this short video series. In this three part discussion they cover the most recent guidelines from ACC, ESC and KDIGO, real-world evidence from the recent ZORA trial and the use of novel potassium binders in optimising guideline directed medical therapy.